Hepatitis is a major cause of healthcare burden in both developed and developing countries. Patients with autoimmune disorders are contributing to the rise in hepatitis prevalence. This steady growth is being aided by an aging population and varying societal behavior. Rising viral infections such as type A, B, C, D, E, and possibly G are the leading causes of hepatitis. Chronic hepatitis can be caused by hepatitis B and C. Acute hepatitis A symptoms include fatigue, flu-like symptoms, and dark urine, whereas chronic hepatitis symptoms are mild and non-specific.
Hepatitis A vaccine is a vaccine designed to protect against the hepatitis A virus. The Hepatitis A vaccine is available for long-term HAV infection prevention. The minimum age for HAV vaccination is one year. The classification of Hepatitis A Vaccine includes Inactivated Vaccine and Live Attenuated Vaccine, with Inactivated Vaccine accounting for approximately 70.8 percent of sales in 2017, with the proportion increasing from 2013 to 2018.
announced that the company's abstract based on the 3-Dose Hepatitis B (HepB) vaccine has been selected for a late-breaker oral presentation at IDWeek 2019, which will be held in Washington, D.C. Furthermore, the 2-dose schedule hepatitis B vaccine is expected to be the fastest-growing segment during the forecast period.
Read More…